XML 14 R2.htm IDEA: XBRL DOCUMENT v3.4.0.3
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2016
Dec. 31, 2015
Current assets:    
Cash and cash equivalents $ 41,624,045 $ 57,632,693
Short-term investments 105,163,382 105,357,277
Accounts receivable 11,152,759 7,333,059
Prepaid expenses and other current assets 1,122,707 917,257
Prepaid expenses and other current assets from affiliated entity 1,538,563 610,652
Total current assets 160,601,456 171,850,938
Fixed assets, net 8,393,322 7,306,695
Investment in affiliated entity- GeneOne 22,422,255 14,941,277
Investment in affiliated entity - PLS 5,026,917 5,045,915
Intangible assets, net 3,696,318 3,905,860
Goodwill 10,113,371 10,113,371
Other assets 1,034,753 676,803
Total assets 211,288,392 213,840,859
Current liabilities:    
Accounts payable and accrued expenses 12,102,303 13,064,899
Accounts payable and accrued expenses due to affiliated entity 207,233 165,047
Accrued clinical trial expenses 4,150,796 2,600,483
Common stock warrants 1,707,387 1,301,138
Deferred revenue 14,538,426 13,449,768
Deferred revenue from affiliated entity 376,042 504,442
Deferred rent 316,617 380,629
Total current liabilities 33,398,804 31,466,406
Deferred revenue, net of current portion 434,695 103,074
Deferred revenue from affiliated entity, net of current portion 367,944 677,371
Deferred rent, net of current portion 5,693,594 5,485,313
Deferred tax liabilities 175,642 175,642
Total liabilities 40,070,679 37,907,806
Inovio Pharmaceuticals, Inc. stockholders’ equity:    
Common stock 72,268 72,218
Additional paid-in capital 537,131,310 534,004,564
Accumulated deficit (369,140,716) (361,097,896)
Accumulated other comprehensive income 2,909,023 2,708,339
Total Inovio Pharmaceuticals, Inc. stockholders’ equity 170,971,885 175,687,225
Non-controlling interest 245,828 245,828
Total stockholders’ equity 171,217,713 175,933,053
Total liabilities and stockholders’ equity $ 211,288,392 $ 213,840,859